Abstract
Transient leukemia (TL) has been observed in approximately 10% of newborn infants with Down syndrome (DS). Although treatment with cytarabine is effective in high-risk TL cases, approximately 20% of severe patients still suffer early death. In this study, we demonstrate abundant KIT expression in all 13 patients with GATA1 mutations, although no significant difference in expression levels was observed between TL and acute myeloid leukemia. Stem cell factor (SCF) stimulated the proliferation of the TL cells from five patients and treatment with the tyrosine kinase inhibitor imatinib suppressed the proliferation effectively in vitro. To investigate the signal cascade, we established the first SCF-dependent, DS-related acute megakaryoblastic leukemia cell line, KPAM1. Withdrawal of SCF or treatment with imatinib induced apoptosis of KPAM1 cells. SCF activated the RAS/MAPK and PI3K/AKT pathways, followed by downregulation of the pro-apoptotic factor BIM and upregulation of the anti-apoptotic factor MCL1. Although we found novel missense mutations of KIT in 2 of 14 TL patients, neither mutation led to KIT activation and neither reduced the cytotoxic effects of imatinib. These results suggest the essential role of SCF/KIT signaling in the proliferation of DS-related leukemia and the possibility of therapeutic benefits of imatinib for TL patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Zipursky A, Brown E, Christensen H, Sutherland R, Doyle J . Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Semin Perinatol 1997; 21: 97–101.
Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 1992; 80: 2210–2214.
Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaizumi M et al. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2007; 25: 5442–5447.
Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, Taub JW et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood 2006; 107: 4606–4613.
Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C et al. Treatment and prognostic impact of transient leukemia in neonates with Down's syndrome. Blood 2008; 111: 2991–2998.
Crispino JD . GATA1 in normal and malignant hematopoiesis. Semin Cell Dev Biol 2005; 16: 137–147.
Bourquin JP, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci USA 2006; 103: 3339–3344.
Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza F et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood 1998; 92: 596–599.
Langebrake C, Creutzig U, Reinhardt D . Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr 2005; 217: 126–134.
Sato T, Toki T, Kanezaki R, Xu G, Terui K, Kanegane H et al. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome. Br J Haematol 2008; 141: 681–688.
Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006; 10: 65–75.
Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 2005; 106: 2484–2490.
Adams JM, Cory S . The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322–1326.
Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ . Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 2003; 278: 18811–18816.
Hirose Y, Kudo K, Kiyoi H, Hayashi Y, Naoe T, Kojima S . Comprehensive analysis of gene alterations in acute megakaryoblastic leukemia of Down's syndrome. Leukemia 2003; 17: 2250–2252.
Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 2007; 13: 5398–5405.
Miyauchi J, Ito Y, Kawano T, Tsunematsu Y, Shimizu K . Unusual diffuse liver fibrosis accompanying transient myeloproliferative disorder in Down's syndrome: a report of four autopsy cases and proposal of a hypothesis. Blood 1992; 8: 1521–1527.
Teyssier-Le Discorde M, Prost S, Nandrot E, Kirszenbaum M . Spatial and temporal mapping of c-kit and its ligand, stem cell factor expression during human embryonic haemopoiesis. Br J Haematol 1999; 107: 247–253.
Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH . Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 2005; 37: 613–619.
Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 2004; 103: 3644–3654.
Pietsch T, Kyas U, Steffens U, Yakisan E, Hadam MR, Ludwig WD et al. Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: heterogeneity in response and synergy with other hematopoietic growth factors. Blood 1992; 80: 1199–1206.
Bataller R, Gabele E, Parsons CJ, Morris T, Yang L, Schoonhoven R et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 2005; 41: 1046–1055.
Hattori H, Matsuzaki A, Suminoe A, Ihara K, Nakayama H, Hara T . High expression of platelet-derived growth factor and transforming growth factor-β1 in blast cells from patients with Down Syndrome suffering from transient myeloproliferative disorder and organ fibrosis. Br J Haematol 2001; 115: 472–475.
Ogawa J, Kanegane H, Tsuneyama K, Kanezaki R, Futatani T, Nomura K et al. Platelet-derived growth factor may be associated with fibrosis in a Down syndrome patient with transient myeloproliferative disorder. Eur J Hematol 2008; 81: 58–64.
Wang S, Wilkes MC, Leof EB, Hirschberg R . Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. Faseb J 2005; 19: 1–11.
Borkham-Kamphorst E, Herrmann J, Stoll D, Treptau J, Gressner AM, Weiskirchen R . Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest 2004; 84: 766–777.
Yoshiji H, Kuriyama S, Noguchi R, Ikenaka Y, Yoshii J, Yanase K et al. Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats. Int J Mol Med 2006; 17: 899–904.
Acknowledgements
We thank Dr K Kageyama (Hirosaki University Graduate School of Medicine) for helpful discussion. We are grateful to Dr K Kawakami, S Morinaga, M Migita, K Kato, H Kanegane, M Miura, T Nakano, T Taga, A Shimada, D Hasegawa for clinical samples. XG is supported by a fellowship from the Ministry of Education, Science, Sports and Culture. This work was supported by Grants-in-Aid for Scientific Research and Grants-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Science, Sports and Culture, and Grants from Ministry of Health Labour and Welfare.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Rights and permissions
About this article
Cite this article
Toki, T., Kanezaki, R., Adachi, S. et al. The key role of stem cell factor/KIT signaling in the proliferation of blast cells from Down syndrome-related leukemia. Leukemia 23, 95–103 (2009). https://doi.org/10.1038/leu.2008.267
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.267
Keywords
This article is cited by
-
Purification of leukemic blast cells from blood smears using laser microdissection
International Journal of Hematology (2017)
-
GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia
Leukemia (2014)
-
Gene profiling of the erythro- and megakaryoblastic leukaemias induced by the Graffi murine retrovirus
BMC Medical Genomics (2010)
-
Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome
Oncogene (2010)
-
Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia
International Journal of Hematology (2010)